Log In
Print
BCIQ
Print
Print this Print this
 

KB003

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionChimeric mAb against GM-CSF developed using Humaneered technology
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory disease
Indication DetailsTreat inflammatory disorders
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today